Search PubMed⌕ Search

Biomedical subjects

Y Terashima

Publications and source records attributed to Y Terashima.

At least 163 records · Page 9Linked to original sources
PubMed1989

[Immunohistochemical localization and significance of ornithine aminotransferase in gut and liver in rats].

This study was performed to elucidate immunohistochemical localization of OAT in the gut mucosa and liver of rats using the ABC method. In the normal rat gut mucosa, strong immunoreactivity of OAT as fine granules was present in the surface epithelial cells and apical portion of intestinal glands. In the liver, this reaction was observed in the range of zone 2 to 3 of the pericentral vein and periportal vein. The changes in the intestinal glands of rats with a hyperprotein intake were observed to peak at 2 weeks, but in the liver a strongly positive diffuse reaction throughout whole lobules was detected at 4 weeks. This immunoreactive morphological localization of OAT suggests the location of absorption of amino acids in the small intestine and the distribution of the urea cycle enzyme OAT in the liver. The relationship between absorption of amino acids in the small intestine and the distribution of OAT in the liver was assumed to facilitate feedback repression. The changes in OAT in the mitochondria showed many diverse patterns by immunochemical electron microscopy, and these reactions are presumed to facilitate various types of metabolism in a single cells.

Animals↗
PubMed1988

The effects of co-administration of selenium and cis-platin (CDDP) on CDDP-induced toxicity and antitumour activity.

The therapeutic antitumour activity and host toxicity of cis-platin (CDDP), which was administered with selenium (sodium selenite) was studied on the growth of a human yolk sac tumour grown in nude mice. Treatment consisted of CDDP single agent chemotherapy (3 weeks) or preliminary PVB combination chemotherapy (CDDP + vinblastine + bleomycin, 2 weeks). Selenium was co-administered from day 1 to 5 with each therapeutic regimen. The administration of CDDP alone caused significant reduction in tumour burden but at higher doses there was significant host toxicity. The co-administration of selenium together with CDDP (CDDP: selenium, molar ratio = 3.5:1) did not affect the anti-tumour activity of CDDP but it did cause a decrease of parameters of host toxicity including lethality, increasing the 50% lethal dose (LD50) from 9.3 mg kg-1 to 17.5 mg kg-1. The parameters of host toxicity which were altered by selenium co-administration were nephrotoxicity, myeloid suppression and weight loss. Our study suggested that selenium co-administration allows higher doses of CDDP with reduction of apparent toxicity, resulting in a higher therapeutic index and possibly indicating a potential increase in the utilization of CDDP in clinical cancer chemotherapy.

Animals↗
PubMed1988

[New technology of diagnosis of ovarian cancer].

It is difficult to identify early ovarian cancer at present. However, some tumor markers (CA125, CA19-9, CEA) and soon imaging system (MRI, CT, UT) and some oncogenes are available for diagnosis of ovarian cancer recently. Multivariate analysis of tumor markers has a possibility of stage I cancer. MRI is very useful to identify some cystic and hemorrhagic lesions. Amplifiers of N-myc and K-ras may be applied to diagnose ovarian cancer. In future, these new technologies may identify early ovarian cancer.

Adenocarcinoma↗
PubMed1988

[A case of cholangiocarcinoma treated by transcatheter arterial embolization].

A case history with a 2 year and 10 month survival, involving a peripheral cholangiocarcinoma that had been treated 3 times by transcatheter (TAE) and radiotherapy is discussed. The main cholangiocarcinoma markedly decreased in size and was found to contain many small calcified deposits after the 3 episodes of TAE.

Adenoma, Bile Duct↗
PubMed1988

[The expression of c-myc, c-fms, c-sis oncogenes in the trophoblast of normal pregnancy and trophoblastic disease].

Recently it has been suggested that proto-oncogene plays a role not only in cellular proliferation, development and differentiation, but also in neoplastic transformation. We now show the expression and its localization of c-myc, c-fms and c-sis proto-oncogenes in human developing chorionic tissue and fresh surgical specimens of mole and choriocarcinoma with the method of Northern blotting and In-situ hybridization. The 2.4kb c-myc transcript has been localized to the cytotrophoblast in early placenta and also localized to the C and S typed trophoblastic cells in mole and choriocarcinoma. The 4.0kb c-fms transcript has been localized to the syncytiotrophoblast, especially the highly differentiated syncytiotrophoblast in the second and third trimesters and S typed trophoblastic cells in mole and choriocarcinoma. Moreover, the 4.0kb c-sis transcript has been localized to the cytotrophoblast in early placenta, but not detected in mole or choriocarcinoma. First, these results suggest that the stage and site specific expression of c-myc, c-fms and c-sis proto-oncogenes are clearly related to the proliferation, development and differentiation of normal trophoblastic cells. Second, the expression of c-myc, c-fms proto-oncogenes may be of particular importance in the tumorigenesis and progression of trophoblastic disease.

Blotting, Northern↗
PubMed1988

[Phase II study of carboplatin in ovarian cancer].

A phase II study of carboplatin was conducted in ovarian cancer by a cooperative study group consisting of 22 institutions nationwide. The overall response rate of 50 evaluable cases was 38.0%. The response rate in cases with no prior chemotherapy was 54.2% and that with prior chemotherapy was 23.1%. In addition, the response rate was 26.3% in cases that received prior CDDP-based chemotherapy. Histologically, the response rate was high in serous cystadenocarcinoma and endometrioid adenocarcinoma. Hematologic toxicities, particularly leukopenia and thrombocytopenia, were frequently observed, but well tolerated, while renal and neurologic toxicities were rare. These results suggested that carboplatin is useful in the treatment of ovarian cancer.

Adenocarcinoma↗
PubMed1988

[Phase III study of carboplatin in ovarian cancer].

A phase III study of carboplatin vs cisplatin in CAP regimen for ovarian cancer was conducted by a cooperative study group consisting of 22 institutions nationwide. The response rate for 23 cases allocated to carboplatin regimen group was 34.8% and 42.1% for 19 cases allocated to cisplatin regimen group. No significant difference was observed between these two regimens in response rates, and no significant differences were noted between the two regimens in each of the clinical toxicities and abnormalities in laboratory findings. Since the carboplatin regimen group did not require hydration, or the use diuretics or antiemetics, these results suggested that carboplatin is more useful in the treatment of ovarian cancer than cisplatin.

Adult↗
PubMed1988

[Phase II study of carboplatin in cervical carcinoma].

A phase II multi-center study of carboplatin for cervical carcinoma was carried out in 22 institutes throughout Japan. The patients registered consisted of 40 women with 39 cervical carcinomas and an endometrial carcinoma, of whom 31 were evaluable. Carboplatin was administered intravenously every 4 weeks at a dose of 400 mg/m2, in cases with no prior therapies and/or P.S. 0-1, and 300 mg/m2 in cases with prior therapies and/or P.S. 2-3. The overall response rate of 31 evaluable cases was 19.4% with 2 cases of CR and 4 cases of PR. The response rates by histological classification were 18.5% (5/27) for squamous cell carcinoma and 25.0% (1/4) for adenocarcinoma. Response rates analysed by lesion sites were 12.5% for primary tumors, 30.0% for local lesions and 20.0% for metastases. The response rate among patients without prior therapies was 14.3%, while those for patients with prior radiotherapy and for prior radiotherapy and chemotherapy were 33.3% and 13.3%, respectively. Major adverse effects observed were nausea and/or vomiting (52.9%), anorexia (44.1%) and malaise (35.3%). Hematologically, thrombocytopenia, leukopenia and anemia were frequently observed (52.9%, 35.3% and 32.4%, respectively). As for renal toxicity, elevation of BUN (2.9%) or serum creatinine (2.9%) and the decrease of creatinine clearance (14.3%) were observed, but they were mild, and tolerable. These results suggest that carboplatin is one of the most useful drugs against cervical carcinoma.

Adenocarcinoma↗
PubMed1988

[A case report of non-functioning adrenal carcinoma diagnosed by percutaneous needle biopsy and which responded to preoperative chemotherapy].

A 51-year-old female complained of right upper abdominal pain. Non-functioning adrenal carcinoma was suspected from the laboratory data of elevated lactate dehydrogenase level and total amount of urinary excretion of 17-ketosteroid. To deny the possibility of other diseases, such as retroperitoneal sarcoma, a percutaneous needle biopsy of the tumor was carried out. As the pathological diagnosis was adrenal carcinoma, pre-operative chemotherapy consisting of cis-dichlorodiammineplatinum (CDDP), adriamycin, 5-fluorouracil, cyclophosphamide and o,p'-DDD was carried out twice. The tumor size decreased after chemotherapy, and we could operate on the patient safely and relatively easily. Almost all of the tumor was replaced by a necrotic mass. However, cancer cells still remained in the peripheral lesion of the tumor, and the pathological diagnosis was the same as that of biopsy specimen. Although chemotherapy of adrenal carcinoma has not been established yet, we believe from the experience of this case that this disease should be treated by chemotherapy including CDDP.

Adrenal Cortex↗
PubMed1988

[Treatment of advanced cancer of the urinary tract with interleukin-2 (IL-2)].

Eight patients with advanced cancer of the urinary tract were treated with recombinant interleukin-2(IL-2) at our department between December, 1985 and September, 1987. Patients were given 5 x 10(5)-4 x 10(6) units of IL-2 by intravenous drip infusion daily. One of five patients who received IL-2 for over 28 days showed 62% regression in size of hepatic metastasis of bladder cancer on computed tomography and another showed marked improvement of Performance Status. The upward tendency of natural killer and lymphokine-activated killer activity of peripheral blood was observed during treatment. Fever, mental disturbance, hypotension and eosinophilia and others were recognized during administration of IL-2, and cardiac failure and disturbance of renal function were also recognized as severe side effect.

Adult↗
PubMed1987

[The prevention of CDDP-induced emesis with a combination regimen including metoclopramide, dexamethasone, droperidol and diphenhydramine].

The dose limiting factors of cisplatinum are nephrotoxicity and emesis. Nephrotoxicity has been reduced by hydration but nausea and vomiting caused by cisplatinum have led to refusal of potentially curative therapy by a number of patients. The prevention of nausea and vomiting by a combination of antiemetic drugs administered to ovarian patients receiving chemotherapy inducing (cisplatinum 50mg/m2, adriamycin 300 mg/m2, cyclophosphamide 300 mg/m2 and 5FU 350 mg/m2) was studied. the combination antiemetic drugs were metoclopramide (1mg/kg), dexamethasone (10mg/m2), droperidol (1mg/m2) and diphenhydramine (20mg/body). These drugs without diphenhydramine were administered intravenously 30 minutes before and 2.5 hours, 5 hours and 7.5 hours after chemotherapy. Diphenhydramine was administered intramuscularly 30 minutes before and 5 hours after chemotherapy. No vomiting was noted in 82.6% (19/23) of cases, and no patient vomited more than four times. This combination regimen provided very good protection against cisplatinum induced emesis.

Adult↗
PubMed1987

Effect of tamoxifen on ultrastructure of endometrial carcinoma.

Tamoxifen is a nonsteroidal antiestrogen whose mode of action is, as yet, unclear. The purpose of this report is to investigate the effects of Tamoxifen on endometrial adenocarcinoma ultrastructurally. Five patients with endometrial adenocarcinoma, 3 cases well differentiated and the others undifferentiated, were treated with 20mg Tamoxifen per os a day for 7 days, and the following changes were observed: The cells became roundish and slightly swollen. Development of cytoplasmic organelles was observed. In the cytoplasm, glycogen granules did not increase. These results suggest that an anti-cancer effect is brought about by the induction of the tissue toward functional differentiation as well as inhibition of glycogen metabolism in tumor cells.

Adenocarcinoma↗
PubMed1986

Effects of sexual steroid hormones treatment on Ca2+ sensitivity of chemically skinned uterine muscle fibers from ovariectomized rats.

We considered the possible relationship between the serum levels of progesterone and estradiol-17 beta, which were controlled to that of several stages in normal pregnant rats, and the Ca2+ sensitivity, defined as the pCa required for half maximum activation of force production, of chemically skinned uterine muscle fibers from ovariectomized rats. The Ca2+ sensitivity was negligibly influenced by the levels of these hormones.

Animals↗